Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life

The STROMA-CoV-2 study was a French phase 2b, multicenter, double-blind, randomized, placebo-controlled clinical trial that did not identify a significant efficacy of umbilical cord-derived mesenchymal stromal cells in patients with SARS-CoV-2-induced acute respiratory distress syndrome. Safety on d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current stem cell research and therapy 2024-04, Vol.15 (1), p.109-109, Article 109
Hauptverfasser:	Sitbon, Alexandre, Hauw-Berlemont, Caroline, Mebarki, Miryam, Heming, Nicholas, Mayaux, Julien, Diehl, Jean-Luc, Demoule, Alexandre, Annane, Djillali, Marois, Clémence, Demeret, Sophie, Weiss, Emmanuel, Voiriot, Guillaume, Fartoukh, Muriel, Constantin, Jean-Michel, Mégarbane, Bruno, Plantefève, Gaëtan, Boucher-Pillet, Hélène, Churlaud, Guillaume, Cras, Audrey, Maheux, Camille, Pezzana, Chloé, Diallo, Mamadou Hassimiou, Lebbah, Said, Ropers, Jacques, Salem, Joe-Elie, Straus, Christian, Menasché, Philippe, Larghero, Jérôme, Monsel, Antoine
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute respiratory distress syndrome Clinical trials Coronaviruses CT imaging Follow-up Studies Health aspects Human health and pathology Infectious diseases Life Sciences Long-term outcomes Medical research Medicine, Experimental Quality of Life at six and twelve months after hospital discharge Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus‐2 Stem cells Umbilical cord‐ derived mesenchymal stromal cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The STROMA-CoV-2 study was a French phase 2b, multicenter, double-blind, randomized, placebo-controlled clinical trial that did not identify a significant efficacy of umbilical cord-derived mesenchymal stromal cells in patients with SARS-CoV-2-induced acute respiratory distress syndrome. Safety on day 28 was found to be good. The aim of our extended study was to assess the 6- and 12-month safety of UC-MSCs administration in the STROMA-CoV-2 cohort. A detailed multi-domain assessment was conducted at 6 and 12 months following hospital discharge focusing on adverse events, lung computed tomography-scan, pulmonary and muscular functional status, and quality of life in the STROMA-CoV-2 cohort including SARS-CoV-2-related early (
ISSN:	1757-6512 1757-6512 1574-888X
DOI:	10.1186/s13287-024-03729-w